Drug Profile


Alternative Names: FK 949; FK949E; ICI 204636; Quetiapine extended release; Quetiapine fumarate; Quetiapine prolonged release; Seroquel; Seroquel XL; Seroquel XR

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Astellas Pharma; AstraZeneca; Hutchison MediPharma
  • Class Analgesics; Antipsychotics; Dibenzothiazepines; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 1 receptor agonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Bipolar disorders; Major depressive disorder; Manic episodes; Schizophrenia
  • Phase III Borderline personality disorders
  • Preregistration Submission Withdrawal Generalised anxiety disorder
  • No development reported Delirium; Irritable bowel syndrome
  • Discontinued Alcoholism; Behavioural disorders; Psychotic disorders

Most Recent Events

  • 31 Jul 2017 Registered for Bipolar disorders in Japan (PO) (Astellas pipeline, July 2017)
  • 01 Nov 2016 First Generic equivalent for SEROQUEL XR® launched in USA
  • 31 Aug 2016 Preregistration for Bipolar disorders in Japan (PO) (Astellas pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top